Gottlieb’s Exit Won’t Slow Work on Drug Competition: FTC Official

March 6, 2019, 7:49 PM

Food and Drug Administration Commissioner Scott Gottlieb’s resignation isn’t likely to change the agency’s increased cooperation with the Federal Trade Commission on drug competition, FTC Commissioner Christine Wilson said March 6.

Under Gottlieb, who announced his resignation on March 5, the FDA has stepped up its focus on drug competition and pledged to bolster FTC efforts to crack down on anticompetitive practices in the pharmaceutical industry.

“That dialogue and cooperation with the FDA will continue in a robust way,” Wilson said at an event sponsored by the Federalist Society in Washington.

Gottlieb has been aggressive on drug competition, vowing to ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.